Pfizer's $43 billion deal for Seagen gets second request from US FTC
Pfizer's proposal to buy cancer biotech firm Seagen got a second request from antitrust enforcers at the US Federal Trade Commission today as the $43 billion gets more scrutiny than prior...To view the full article, register now.
Already a subscriber? Click here to view full article